<DOC>
	<DOCNO>NCT01686711</DOCNO>
	<brief_summary>To evaluate efficacy safety coadministration AD-4833 SYR-322 patient diabetes mellitus .</brief_summary>
	<brief_title>A Double-blind , Parallel Group , Comparative Study Coadministration AD-4833 SYR-322</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Those judge capable understand comply protocol requirement investigator subinvestigator . Those sign date write , informed consent form prior initiation study procedure . Those concurrent serious cardiac disease , serious cerebrovascular disorder , serious pancreatic hematological disease etc . Others assess ineligible study investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>